/
CTOR
$0.69+$0.07 (+11.50%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$57.6M
93M shares
52-week range
$0.49 – $5.89
4% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
3.62%
Moderate
Price (6 mo)
Loading chart…
Change$-2.51
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — |
| R&D | $6.9M | $4.2M | $4.9M | $6.4M |
| Operating income | −$9.7M | −$12.1M | −$20.6M | −$23.5M |
| EBITDA | $0 | −$12.1M | −$20.6M | −$23.5M |
| Net income | −$10.9M | −$12.7M | −$21.1M | −$24.8M |
| Net margin | — | — | — | — |
| EPS (diluted) | -0.08 | -0.19 | -0.30 | -0.34 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $21M | $-0.52 | $-0.52–$-0.52 | 1 |
| 2027 | $95M | $0.10 | $0.10–$0.10 | 1 |
| 2028 | $157M | $0.46 | $0.46–$0.46 | 1 |
| 2029 | $177M | $0.53 | $0.53–$0.53 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.11
Price
$0.69
Implied downside
-85%
Peer comparison
Citius Oncology, Inc. Common Stock
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
www.citiusonc.com- IPO / List date
- Aug 13, 2024
- HQ
- CRANFORD, NJ
Held by traders on TradeandTell
No one on the platform currently holds CTOR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 55,900 | $113.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CTOR yet.
